Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

596 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.
van Besien K, Thall P, Korbling M, Pugh WC, Khouri I, Mehra R, Giralt S, Anderlini P, Amin K, Mirza N, Seong D, Gajewski J, Hester J, Andersson B, Cabanillas F, Champlin R, Przepiorka D. van Besien K, et al. Among authors: amin k. Biol Blood Marrow Transplant. 1997 Aug;3(3):150-6. Biol Blood Marrow Transplant. 1997. PMID: 9310192 Clinical Trial.
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. Popat U, et al. Among authors: amin k. J Clin Oncol. 1998 Jan;16(1):63-9. doi: 10.1200/JCO.1998.16.1.63. J Clin Oncol. 1998. PMID: 9440724
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M, Maynard V, Stock W, Peace D, Ravandi F, Chen YH, Cheung T, Vijayakumar S, Hoffman R, Sosman J. van Besien K, et al. Among authors: amin k. Bone Marrow Transplant. 2003 Jul;32(1):9-13. doi: 10.1038/sj.bmt.1704088. Bone Marrow Transplant. 2003. PMID: 12815472 Clinical Trial.
Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K. Devine SM, et al. Among authors: amin k. Bone Marrow Transplant. 2001 Sep;28(6):557-62. doi: 10.1038/sj.bmt.1703198. Bone Marrow Transplant. 2001. PMID: 11607768 Clinical Trial.
Activation of p55 tumor necrosis factor-alpha receptor-1 coupled to tumor necrosis factor receptor-associated factor 2 stimulates intercellular adhesion molecule-1 expression by modulating a thapsigargin-sensitive pathway in human tracheal smooth muscle cells.
Amrani Y, Lazaar AL, Hoffman R, Amin K, Ousmer S, Panettieri RA Jr. Amrani Y, et al. Among authors: amin k. Mol Pharmacol. 2000 Jul;58(1):237-45. doi: 10.1124/mol.58.1.237. Mol Pharmacol. 2000. PMID: 10860946
596 results